68-5

93/120

Hattori N, Taniguchi A, Morita M, Kano O, Shibuya K, Kuwabara S, Suzuki N, Aoki M, Aiba I, Mizoguchi K, Oda M, Kaji R, Sobue G: Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. J Neurol Neuro‑surg Psychiatry, 2020; 91: 285-290. doi:10.1136/jnnp-2019-322213. ＊ 25) Hayashida A, Li Y, Yoshino H, Daida K, Ikeda A, Ogaki K, Fuse A, Mori A, Takanashi M, Nakahara T, Yoritaka A, Tomizawa Y, Furu‑kawa Y, Kanai K, Nakayama Y, Ito H, Ogino M, Hattori Y, Hattori T, Ichinose Y, Taki‑yama Y, Saito T, Kimura T, Aizawa H, Shoji H, Mizuno Y, Matsushita T, Sato M, Sekijima Y, Morita M, Iwasaki A, Kusaka H, Tada M, Tanaka F, Sakiyama Y, Fujimoto T, Nagara Y, Kashihara K, Todo H, Nakao K, Tsuruta K, Yoshikawa M, Hara H, Yokote H, Murase N, Nakamagoe K, Tamaoka A, Takamiya M, Morimoto N, Nokura K, Kako T, Funayama M, Nishioka K, Hattori N: The identified clin‑ical features of Parkinson’s disease in homo-, heterozygous and digenic variants of PINK1. Neurobiol Aging, 2020: S0197-4580(20)30210-4. 26) Ikenouchi Y, Kamagata K, Andica C, Hatano T, Ogawa T, Takeshige-Amano H, Kamiya K, Wada A, Suzuki M, Fujita S, Hagiwara A, Irie R, Hori M, Oyama G, Shimo Y, Umemura A, Hattori N, Aoki S: Evaluation of white matter microstructure in patients with Parkin‑son’s disease using microscopic fractional anisotropy. Neuroradiology, 2020; 62: 197-203. doi: 10.1007/s00234-019-02301-1. Epub 2019 Nov 4. PubMed PMID: 31680195. 27) Irie R, Otsuka Y, Hagiwara A, Kamagata K, Kamiya K, Suzuki M, Wada A, Maekawa T, Fujita S, Kato S, Nakajima M, Miyajima M, Motoi Y, Abe O, Aoki S: A Novel Deep Learning Approach with a 3D Convolutional Ladder Network for Differential Diagnosis of Idiopathic Normal PressureHydrocephalus and Alzheimer’s Disease Magn Reson Med Sci, 2020; 19: 351. 28) Ito M, Sasaki F, Katsuta N, Sekimoto S, Jo T, Nakamura R, Nakajima A, Oyama G, Shimo Y, Iwamuro H, Umemura A, Ohnuma T, Hattori N: Young age and severity of motor function are risk factors for psychosis after subthalamic nucleus deep brain stimulation for Parkinson’s disease. Psychiatry Clin Neurosci, 2020; 74: 328-329. doi: 10.1111/pcn. 12991. 29) Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, Miyaue N, Yabe H, Nagai M, Nomoto M: A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease. J Neurol Sci. 2020; 414: 116833. 30) Kamiya K, Kamagata K, Ogaki K, Hatano T, Ogawa T, Takeshige-Amano H, Murata S, Andica C, Murata K, Feiweier T, Hori M, Hattori N, Aoki S: Brain White-Matter Degeneration Due to Aging and Parkinson Disease as Revealed by Double Diffusion Encoding. Front Neurosci, 2020; 14: 584510. doi: 10.3389/fnins.2020.584510. PMID: 33177985; PMCID: PMC7594529.＊ 31) Kano M, Takanashi M, Oyama G, Yoritaka A, Hatano T, Shiba-Fukushima K, Nagai M, Nishiyama K, Hasegawa K, Inoshita T, Ishi‑kawa KI, Akamatsu W, Imai Y, Bolognin S, Schwamborn JC, Hattori N: Reduced astro‑cytic reactivity in human brains and midbrain organoids with PRKN mutations. NPJ Parkin‑sons Dis, 2020; 6: 33. doi: 10.1038/s41531-020-00137-8. 32) Kataura T, Saiki S, Ishikawa KI, Akamatsu W, Sasazawa Y, Hattori N, Imoto M: BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkin‑son’s disease model. J Neurochem, 2020; 155: 81-97. doi:10.1111/jnc.14997. 33) Kataura T, Tashiro E, Nishikawa S, Shiba‑hara K, Muraoka Y, Miura M, Sakai S, Katoh N, Totsuka M, Onodera M, Shin-Ya K, Miya‑moto K, Sasazawa Y, Hattori N, Saiki S, Imoto M: A chemical genomics-aggrephagy inte‑grated method studying functional analysis of autophagy inducers. Autophagy, 2020; 1-17. doi:10.1080/15548627.2020.1794590. 34) Kikuno M, Ueno Y, Shimizu T, Kuriki A, Tateishi Y, Doijiri R, Shimada Y, Takekawa H, Yamaguchi E, Koga M, Kamiya Y, Ihara M, Tsujino A, Hirata K, Toyoda K, Hasegawa Y, Aizawa H, Hattori N, Urabe T: CHAL‑LENGE ESUS/C.S. collaborators. Underlying embolic and pathologic differentiation by cere‑543